Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08165784 in PIK3CA-mutated advanced or metastatic solid tumors
NCT07897721Phase 1Not yet recruiting
- Sponsor
- Pfizer
- Start
- Nov 2026
- Primary completion
- Mar 2030
01
Overview
Phase 1, open-label trial of PF-08165784 in breast cancer and colorectal cancer (CRC) (5 cohorts), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
PF-08165784
03
Conditions
breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07897721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897721.